Dr Reddy's measures for success

India''s Dr Reddy''s Laboratories has launched roadshows for a debut ADR that will mark the first US listing attempt by an Asian pharmaceutical company.
March 29, 2001
Investor presentations for an 11.5 million unit issue began in Asia yesterday (Thursday), with final pricing provisionally scheduled for April 11 after the completion of roadshows in Europe and the US next week. With Merrill Lynch as lead manager, the company is hoping to raise about $158 million based on today's close share price of Rp1,285 ($27.59). Each ADR unit equals two shares and the overall offering will comprise about 18% of the company's share capital. With ABN Amro and CLSA as co-managers, there is also a 15% greenshoe.

India's fourth largest pharmaceuticals company by market capitalization, Dr Reddy's is hoping to become the country's first this year to venture into the international equity markets and complete a full New York Stock Exchange (NYSE) listing. But bankers believe that its decision to launch a straight equity deal at a time of continuing market uncertainty remains well founded.

Sign in to read on!

Registered users get 2 free articles in 30 days.

Subscribers have full unlimited access to FinanceAsia.

Not signed up? New users get 2 free articles per month, plus a 7-day unlimited free trial.

Questions?
See here for more information on licences and prices, or contact [email protected].

Related Articles

Reddy for reform

Reform of India''s debt market may be cautious, but in the last three years, the results have been dramatic, says Dr. YV Reddy of the Reserve Bank of India.
June 20, 2000

Marcel Desailly talks success

In an excerpt from this month's upcoming FinanceAsia magazine, legendary French footballer Marcel Desailly reflects on what success means.
February 14, 2012